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Fluconazole (UK-49,858) is a new oral bis-triazole antifungal agent with demonstrated activity against
Candida albicans. Because of the increasing importance of infections due to other species of Candida, we studied
the efficacy of fluconazole in a rat model of established systemic candidiasis, using clinical isolates of C.
tropicalis, C. glabrata, and C. krusei. In normal rats, oral fluconazole at both 20 and 80 mg/kg per day for 7
days reduced both kidney and liver titers of C. tropicalis and C. glabrata compared with those in control animals
and was only slightly inferior to amphotericin B. Both fluconazole and amphotericin B were ineffective in
reducing kidney titers of C. krusei, but amphotericin B was more effective than fluconazole in reducing liver
titers. Fluconazole showed no increased efficacy at the higher dose of 80 mg/kg per day compared with 20 mg/kg
per day in any experiment. These results suggest that oral fluconazole may be useful in the treatment of
established disseminated candidiasis caused by species other than C. albicans. Further in vivo studies are
needed, however, to define minimum effective doses and length of therapy and to test additional Candida
isolates.
Infections with Candida species are an important cause of
morbidity and mortality in immunocompromised patients.
Fungemia and disseminated candidiasis have been associ-
ated with malignancy, broad-spectrum antibiotics, cytotoxic
drugs, and total parenteral nutrition (5, 6, 10). Although
Candida albicans is the most common species found, there
has been a marked increase in the number of serious
infections in these patients caused by other Candida species,
including C. tropicalis, C. krusei, C. parapsilosis, and C.
glabrata (1, 3, 5, 8, 9, 17). Amphotericin B is the standard
therapy for serious infections due to Candida species, but
may be associated with significant toxicity. More infections
are occurring with species of Candida resistant to ampho-
tericin B (2). Additional drugs, therefore, are needed for
both prophylaxis and treatment of infections caused by
Candida species.
Fluconazole (UK-49,858), an investigational bis-triazole
antifungal agent, has been shown to have excellent activity
against systemic candidiasis caused by C. albicans in normal
and immunosuppressed animals (11-13, 16). Advantages of
fluconazole include its high levels in serum after oral admin-
istration and minimal toxicity even at high doses. To our
knowledge, however, the efficacy of fluconazole in the
treatment of Candida infections caused by species other
than C. albicans has not been studied. The purpose of this
study was to compare the efficacy of oral fluconazole with
that of amphotericin B in a model of disseminated candidi-
asis, using clinical isolates of C. tropicalis, C. krusei, and C.
glabrata.
(This work was presented in part at the Annual Meeting of
the American Society for Microbiology, May 1988 [J. Had-
dad, M. A. Fisher, W. F. Tarry, and S. H. Shen, Abstr.
Annu. Meet. Am. Soc. Microbiol. 1988, A122, p. 21].)
* Corresponding author.
MATERIALS AND METHODS
Animals. Outbred male Sprague-Dawley rats, 225 to 250 g,
were housed in groups of five to seven per cage with free
access to water and rodent chow (Wayne Pet Food, Conti-
nental Grain Co., Chicago, Ill.). After 7 days of acclimati-
zation, the rats were randomly assigned to experimental
groups.
Compounds. Fluconazole (UK-49,858; lot R-9) was pro-
vided by Pfizer, Inc., Groton, Conn. This compound was
preweighed at weekly intervals into sterile tubes and stored
at -70°C until the day of use. Solubilization was performed
by warming the powder to room temperature, adding suffi-
cient sterile distilled water to make a 5-mg/ml solution, and
vortexing until the powder dissolved. Amphotericin B (Fun-
gizone; control 6C86692), provided in part by E. R. Squibb
& Sons, Princeton, N.J., was reconstituted with 10 ml of
sterile distilled water, and final suspensions for administra-
tion were prepared by dilution with a 5% glucose injection
USP with a pH of 4.6, yielding a concentration of 0.3 mg/ml.
Inocula. Clinical blood isolates of C. tropicalis, C. gla-
brata, and C. krusei stored at -70°C in 1-ml aliquots were
used for fresh subcultures on Sabouraud dextrose agar plates
(Difco Laboratories, Detroit, Mich.), prepared 24 h prior to
inoculation, and incubated at 37°C. The C. tropicalis isolate
was provided by John E. Bennett, National Institutes of
Health, Bethesda, Md. The C. glabrata and C. krusei
isolates were blood isolates from patients at West Virginia
University Hospitals, Inc., who had had disseminated can-
didiasis. A 10-ml portion of nonbacteriostatic normal saline
was used to suspend subcultured organisms on the day of
inoculation, using sufficient organisms to produce a turbid
suspension when vortexed. A portion of suspension was
then adjusted by serial dilutions in saline to correspond to a
McFarland standard of 0.5 which consistently produced a
concentration of 106 CFU/ml. The following inocula were
used for injection: C. tropicalis, 107 CFU/ml; C. glabrata,












found in preliminary experiments to infect >90% of animals
without early lethality, using the present methods.) Verifi-
cation of the original concentration of each isolate was done
with serial 10-fold dilutions of the original suspension cul-
tured on Sabouraud dextrose agar by using the pour plate
technique, incubating at 37°C for 48 h, and counting the CFU
per milliliter. Each rat was injected in a lateral tail vein with
0.2 ml of prepared suspension of one of the Candida species.
Treatment regimens. Drug therapy was begun 3 days after
inoculation. Groups of rats inoculated with the various
Candida species were randomly assigned to one of our four
treatment groups: amphotericin B, 1.0 mg/kg per day intra-
peritoneally; fluconazole, 20 mg/kg per day by gavage given
once a day with a blunt metal cannula; fluconazole, 40 mg/kg
given twice daily by gavage; or control group, 3.33 ml of
distilled water-glucose solution per kg given intraperitone-
ally (a volume equal to that of the amphotericin preparation).
For the C. tropicalis and C. krusei experiments, each treat-
ment group consisted initially of 10 rats. For the C. glabrata
trial, five rats were present in each group at the beginning of
therapy.
All rats were treated for 7 days and then sacrificed by
pentabarbital injection 2 days after the last treatment.
Culture techniques and statistics. Both kidneys were ster-
ilely excised and decapsulated. Approximately half of each
kidney was weighed and homogenized in 1 ml of sterile
saline. A segment of liver from each rat was treated simi-
larly. Aliquots of 0.1 ml of homogenate were then cultured
on Sabouraud dextrose agar pour plates in duplicate, with
two 100-fold dilutions of each homogenate, inverted, and
incubated for 48 h at 37°C.
The CFU per gram of tissue for each kidney and liver from
each rat was converted to log10 for statistical manipulation.
This culture technique does not detect <10 CFU/g reliably,
so all samples with 0 CFU/g were assigned a log1o = 0
corresponding to 1 CFU/g. Analysis of variance was used to
compare mean log colony counts of kidneys of various
treatment groups; the liver counts were analyzed separately.
Fisher's exact test was used to compare the numbers of
animals in each treatment group in an experiment which had
negative kidney or liver cultures. A P value of <0.05 was
considered to be statistically significant.
In vitro susceptibility testing. In vivo susceptibility studies
were done by S. White and S. Shadomy, using a modification
of broth macrodilution methods described previously and
used for other antifungal agents (9, 15, 18). Amphotericin B
was tested in antibiotic medium 3 FDA (Penassay broth
0243; Difco). Fluconazole testing was performed in synthetic
amino acid medium-fungal (provided by M. G. Rinaldi,
University of Texas Health Science Center at San Antonio,
and available commercially from American Biorganic, Inc.,
North Tonawanda, N.Y.). Amphotericin B solution was
prepared by dissolving the stabilized deoxycholate suspen-
sion in 100% dimethyl sulfoxide to yield a stock solution
concentration of 5,000 ,ug/ml. Further twofold serial dilu-
tions were accomplished in antibiotic medium 3 FDA to
prepare final test concentrations ranging from 100 to 0.05
,ug/ml. The test concentrations were placed in 1-ml dispos-
able tubes (Falcon 2054 plastic tubes) in 1.0-ml volumes and
were prepared fresh and used the same day. A 5-mg amount
of fluconazole was dissolved in 5 ml of water, resulting in a
stock concentration of 5,000 ,ug/ml. The antimycotic was
further serially diluted to achieve test concentrations ranging
from 100 to 0.05 ,ug/ml. The test concentrations were dis-
pensed in 1-ml volumes in plastic tubes and used as de-
scribed above.
TABLE 1. C. tropicalis mean colony counts
No. of Log1o CFU/g of tissue ± SETreatment rtTreatmetrats Kidneya Liver'
Amphotericin B 9 3.87 ± 0.11 0.65 ± 0.26
Fluconazole
80 mg/kg per day 9 4.47 ± 0.18 0.95 ± 0.31
20 mg/kg per day 10 4.44 ± 0.10 1.01 ± 0.28
Control 9 5.14 ± 0.19 2.86 ± 0.21
a Mean for right and left kidneys. Fluconazole (both regimens) versus
control, P < 0.05; amphotericin B lower than fluconazole (either regimen), P
< 0.05.
b Fluconazole (both regimens) versus control, P < 0.05; amphotericin B
lower than fluconazole (either regimen), P < 0.05.
A control organism, Saccharomyces cerevisiae (ATCC
9763), as well as the isolates of C. tropicalis, C. glabrata,
and C. krusei used for the infection studies, were prepared
for susceptibility testing by growing each isolate on Sab-
ouraud dextrose agar slants at 30°C for 48 h. Testing of each
Candida isolate was done as follows. A loopful of each
organism was removed from the overnight slant and sus-
pended in 5 ml of sterile saline. The saline suspension was
adjusted to provide a reading of 95% transmittance when
measured in a spectrophotometer (Bausch & Lomb) set at
530 nm. This reading corresponded to approximately 106
CFU/ml and was verified by plate counts. The test medium
was inoculated (95% suspension) into 12 test tubes at con-
centrations ranging from 100 to 0.05 jig/ml in duplicates,
using 1-ml pipettes. MICs were determined visually at the
time growth became turbid in the growth control tubes,
usually at 48 h. The MIC was defined as the lowest concen-
tration of antifungal agent which prevented clearly visible
growth.
RESULTS
C. tropicalis. Fluconazole at 20 mg/kg per day reduced
kidney C. tropicalis titers compared with the control (P <
0.05), but amphotericin B was more effective (P < 0.05)
(Table 1). There was no further reduction in kidney yeast
titers with fluconazole at 80 mg/kg per day orally (P = 0.69).
The results were similar in the liver. With amphotericin B,
five of nine rats showed negative liver cultures; with flucon-
azole at 80 mg/kg per day, 4 of 9 rats did so; and with
fluconazole at 20 mg/kg per day, 4 of 10 rats did so. None of
10 control rats had negative liver cultures (P > 0.05). No
deaths occurred in any group until sacrifice. The MIC of
amphotericin B for the C. tropicalis isolate was 0.39 ,ug/ml,
and that of fluconazole was 100 ,ug/ml.
C. glabrata. Fluconazole at both 20 and 80 mg/kg per day
reduced kidney C. glabrata titers compared with the control
(P < 0.05) and was as effective as amphotericin B (P > 0.05)
(Table 2). In the liver, both fluconazole and amphotericin B
reduced C. glabrata colony counts compared with the
control (P < 0.05). In this case, the fluconazole was less
effective than amphotericin B and only marginally more
effective than the control. There were no rats in any group
with negative cultures. Two rats in the amphotericin B group
died on day 1 of treatment. The MIC of amphotericin B for
C. glabrata was 0.2 ,ug/ml, and the fluconazole MIC was 100
xg/ml.
C. krusei. Achieving a high rate of infection in our rat
model was possible only by using a very high (109 CFU/ml)
inoculum of C. krusei. Once infection was established,
however, it was difficult to reduce colony counts with a
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TABLE 2. C. glabrata mean colony counts
No. of Loglo CFU/g of tissue + SETreatment rats bras Kidney' Liverb
Amphotericin B 3 3.04 ± 0.33 2.47 ± 0.32
Fluconazole
80 mg/kg per day 5 3.01 ± 0.17 3.06 ± 0.14
20 mg/kg per day 5 3.10 ± 0.25 3.19 ± 0.21
Control 3 6.01 ± 0.28 3.61 ± 0.11
a Mean for right and left kidneys. All therapy groups lower than control, P
< 0.05.
b Amphotericin B lower than any other regimen, P < 0.05.
7-day course of any regimen studied. There were no rats in
any group that had negative kidney or liver cultures, and
there were no deaths before sacrifice. Both fluconazole and
amphotericin B were ineffective in reducing kidney titers of
C. krusei (P > 0.05) (Table 3). Amphotericin B was more
effective than fluconazole in reducing liver C. krusei titers (P
< 0.05). As in the previous experiments, fluconazole showed
no increased efficacy at the higher dose of 80 mg/kg per day.
The MIC of amphotericin B for the C. krusei isolate was 0.78
Lg/ml, and that of fluconazole was 100 ,ug/ml.
DISCUSSION
Antifungal agents used for either prophylaxis or empiric
therapy in immunocompromised patients should be active
optimally against C. albicans as well as other Candida
species. In our rat model, we found that fluconazole was
effective in reducing tissue titers of one isolate of C. tropi-
calis and one isolate of C. glabrata. In contrast, fluconazole
was ineffective in reducing titers of C. krusei, while ampho-
tericin B reduced liver titers by only 1 log. This relatively
poor response to amphotericin B by the C. krusei isolate may
have been due to the intermediate susceptibility to ampho-
tericin as measured by MIC testing (MIC, 0.78 Kxg/ml). The
observation that fluconazole was ineffective against the C.
krusei isolate may be important because the two antifungal
agents work via different mechanisms (7, 14). This possible
cross-resistance should be sought in other amphotericin
B-insusceptible isolates with longer treatment courses be-
fore any conclusions should be drawn. We also tested two
human blood isolates of C. parapsilosis, but the efficacy of
drugs could not be assessed because neither strain used was
pathogenic in our rat model even with an inoculum of 109
CFU/ml.
The Candida concentrations required to produce infection
reliably in our rat model were high, ranging from 107 to 109
CFU/ml. This situation may not be analogous to the devel-
opment of disseminated candidiasis in humans. The final
Candida tissue titers achieved in control animals, however,
TABLE 3. C. krusei mean colony counts
No. of Loglo CFU/g of tissue + SE
Treatmentrats Kidney' Liverb
Amphotericin B 10 2.13 ± 0.34 2.48 ± 0.38
Fluconazole
80 mg/kg per day 10 2.87 ± 0.16 3.72 ± 0.22
20 mg/kg per day 10 2.41 ± 0.37 3.76 ± 0.27
Control 10 2.67 ± 0.27 3.75 ± 0.12
a Mean for right and left kidneys. Means not different, P > 0.05.
b Amphotericin B lower than any other regimen, P < 0.05.
were similar to those produced by lower inocula of C.
albicans in our experiments. It is likely that lower inocula of
C. tropicalis, C. glabrata, and C. krusei would produce a
similar degree of infection in immunosuppressed animals.
Although fluconazole at both 20 and 80 mg/kg per day was
effective in reducing both liver and kidney titers of C.
tropicalis as well as C. glabrata, fluconazole was generally
less effective than amphotericin B in our model. Two am-
photericin B-treated rats in the C. glabrata experiment died
after receiving only one dose. It is possible that the apparent
advantage of amphotericin B may have been less had these
animals survived and if Candida colony counts could have
been measured. A larger sample size of animals would be
needed to resolve this issue.
No improvement in efficacy was seen with the higher dose
of fluconazole. This observation may result from the fact
that the primary mechanism of action of fluconazole is
inhibition of ergosterol synthesis by targeting of a single
enzyme in the pathway. Its activity may be limited by the
kinetics of the drug-enzyme interaction or the degree of
enzyme inhibition produced by drug binding, since absorp-
tion is nearly complete and distribution to the kidney is
particularly efficient (13). Thus, although the higher dose
given twice a day overcomes the problem of a short half-life
(4 h) in the rat (4), enzyme saturation at low drug concen-
tration or incomplete enzyme inhibition by the drug may
preclude realization of greater benefit from the high levels in
serum achievable without apparent side effects.
The high MICs of fluconazole when tested in synthetic
amino acid medium-fungal did not correlate with the efficacy
of the drug in our model against the isolates of C. tropicalis
or C. glabrata used. When complex media are used for in
vitro testing of fluconazole, the results may be falsely high
and may not correlate with clinical efficacy (13). In our
fluconazole testing, even with the essential medium syn-
thetic amino acid medium-fungal, the MICs were still high,
emphasizing the problem of discrepancies between in vitro
and in vivo susceptibilities of Candida isolates to fluconazole
(14).
Fluconazole has been shown to be effective in treating C.
albicans infections and superior to ketoconazole in several
animal models (13, 16). Although in our study fluconazole
showed less efficacy against Candida species than ampho-
tericin B, there are potential advantages to this antifungal
agent, including a low toxicity profile and oral administra-
tion.
Fluconazole showed promise in its activity against C.
tropicalis and C. glabrata in the rat model. Further trials are
needed in both humans and animals to test this agent against
more isolates of Candida species, using prolonged therapy,
determining optimal dosages, and assessing efficacy in neu-
tropenic models.
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